vs
Fortune Brands Innovations, Inc.（FBIN）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Fortune Brands Innovations, Inc.の直近四半期売上が大きい（$1.1B vs $772.1M、Revvityの約1.4倍）。Revvityの純利益率が高く（12.7% vs 7.1%、差は5.7%）。Revvityの前年同期比売上増加率が高い（5.9% vs -2.4%）。Fortune Brands Innovations, Inc.の直近四半期フリーキャッシュフローが多い（$183.7M vs $161.8M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs -1.5%）
フォーチュン・ブランズ・イノベーションズ社は米国の住宅・セキュリティ製品メーカーで、本社はイリノイ州ディアフィールドに所在し、フォーチュン500及びS&P400種指数の構成銘柄です。傘下にMoen、Master Lockをはじめ多数のブランドを保有し、2021年末時点の従業員数は約2万8000人です。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
FBIN vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.1B | $772.1M |
| 純利益 | $76.3M | $98.4M |
| 粗利率 | 43.8% | — |
| 営業利益率 | 11.3% | 14.5% |
| 純利益率 | 7.1% | 12.7% |
| 売上前年比 | -2.4% | 5.9% |
| 純利益前年比 | -27.3% | 3.9% |
| EPS（希薄化後） | $0.63 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.1B | $649.9M |
| Q4 25 | $76.3M | $98.4M | ||
| Q3 25 | $70.8M | $46.7M | ||
| Q2 25 | $100.3M | $53.9M | ||
| Q1 25 | $51.4M | $42.2M | ||
| Q4 24 | $105.0M | $94.6M | ||
| Q3 24 | $136.6M | $94.4M | ||
| Q2 24 | $133.9M | $55.4M | ||
| Q1 24 | $96.4M | $26.0M |
| Q4 25 | 43.8% | — | ||
| Q3 25 | 45.2% | 53.6% | ||
| Q2 25 | 45.1% | 54.5% | ||
| Q1 25 | 44.0% | 56.5% | ||
| Q4 24 | 46.0% | — | ||
| Q3 24 | 45.9% | 56.3% | ||
| Q2 24 | 43.6% | 55.7% | ||
| Q1 24 | 43.9% | 54.6% |
| Q4 25 | 11.3% | 14.5% | ||
| Q3 25 | 11.0% | 11.7% | ||
| Q2 25 | 14.3% | 12.6% | ||
| Q1 25 | 9.4% | 10.9% | ||
| Q4 24 | 16.1% | 16.3% | ||
| Q3 24 | 17.8% | 14.3% | ||
| Q2 24 | 16.1% | 12.4% | ||
| Q1 24 | 14.0% | 6.8% |
| Q4 25 | 7.1% | 12.7% | ||
| Q3 25 | 6.2% | 6.7% | ||
| Q2 25 | 8.3% | 7.5% | ||
| Q1 25 | 5.0% | 6.4% | ||
| Q4 24 | 9.5% | 13.0% | ||
| Q3 24 | 11.8% | 13.8% | ||
| Q2 24 | 10.8% | 8.0% | ||
| Q1 24 | 8.7% | 4.0% |
| Q4 25 | $0.63 | $0.86 | ||
| Q3 25 | $0.59 | $0.40 | ||
| Q2 25 | $0.83 | $0.46 | ||
| Q1 25 | $0.42 | $0.35 | ||
| Q4 24 | $0.84 | $0.77 | ||
| Q3 24 | $1.09 | $0.77 | ||
| Q2 24 | $1.06 | $0.45 | ||
| Q1 24 | $0.76 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $264.0M | $919.9M |
| 総負債低いほど良い | $2.5B | — |
| 株主資本純資産 | $2.4B | $7.3B |
| 総資産 | $6.5B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 1.07× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $264.0M | $919.9M | ||
| Q3 25 | $223.9M | $931.4M | ||
| Q2 25 | $234.7M | $991.8M | ||
| Q1 25 | $340.0M | $1.1B | ||
| Q4 24 | $381.1M | $1.2B | ||
| Q3 24 | $344.8M | $1.2B | ||
| Q2 24 | $352.6M | $2.0B | ||
| Q1 24 | $359.7M | $1.7B |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $2.4B | $7.3B | ||
| Q3 25 | $2.4B | $7.4B | ||
| Q2 25 | $2.3B | $7.6B | ||
| Q1 25 | $2.3B | $7.6B | ||
| Q4 24 | $2.4B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.3B | $7.9B | ||
| Q1 24 | $2.3B | $7.8B |
| Q4 25 | $6.5B | $12.2B | ||
| Q3 25 | $6.5B | $12.1B | ||
| Q2 25 | $6.6B | $12.4B | ||
| Q1 25 | $6.6B | $12.4B | ||
| Q4 24 | $6.6B | $12.4B | ||
| Q3 24 | $6.6B | $12.8B | ||
| Q2 24 | $6.7B | $13.4B | ||
| Q1 24 | $6.8B | $13.4B |
| Q4 25 | 1.07× | — | ||
| Q3 25 | 0.91× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.10× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.15× | — | ||
| Q1 24 | 1.17× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $208.2M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $183.7M | $161.8M |
| FCFマージンFCF / 売上 | 17.0% | 21.0% |
| 設備投資強度設備投資 / 売上 | 2.3% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 2.73× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $366.8M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $208.2M | $182.0M | ||
| Q3 25 | $204.4M | $138.5M | ||
| Q2 25 | $149.4M | $134.3M | ||
| Q1 25 | $-83.4M | $128.2M | ||
| Q4 24 | $272.3M | $174.2M | ||
| Q3 24 | $205.3M | $147.9M | ||
| Q2 24 | $261.5M | $158.6M | ||
| Q1 24 | $-71.3M | $147.6M |
| Q4 25 | $183.7M | $161.8M | ||
| Q3 25 | $177.0M | $120.0M | ||
| Q2 25 | $118.7M | $115.5M | ||
| Q1 25 | $-112.6M | $112.2M | ||
| Q4 24 | $212.1M | $149.8M | ||
| Q3 24 | $175.6M | $125.6M | ||
| Q2 24 | $222.7M | $136.6M | ||
| Q1 24 | $-135.9M | $129.7M |
| Q4 25 | 17.0% | 21.0% | ||
| Q3 25 | 15.4% | 17.2% | ||
| Q2 25 | 9.9% | 16.0% | ||
| Q1 25 | -10.9% | 16.9% | ||
| Q4 24 | 19.2% | 20.5% | ||
| Q3 24 | 15.2% | 18.4% | ||
| Q2 24 | 18.0% | 19.7% | ||
| Q1 24 | -12.2% | 20.0% |
| Q4 25 | 2.3% | 2.6% | ||
| Q3 25 | 2.4% | 2.6% | ||
| Q2 25 | 2.6% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 5.5% | 3.4% | ||
| Q3 24 | 2.6% | 3.3% | ||
| Q2 24 | 3.1% | 3.2% | ||
| Q1 24 | 5.8% | 2.7% |
| Q4 25 | 2.73× | 1.85× | ||
| Q3 25 | 2.89× | 2.97× | ||
| Q2 25 | 1.49× | 2.49× | ||
| Q1 25 | -1.62× | 3.03× | ||
| Q4 24 | 2.59× | 1.84× | ||
| Q3 24 | 1.50× | 1.57× | ||
| Q2 24 | 1.95× | 2.87× | ||
| Q1 24 | -0.74× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FBIN
| Wholesale Retail Trade | $526.7M | 49% |
| Home Center Retailer | $257.1M | 24% |
| Security Segment | $165.8M | 15% |
| Other Retailer | $118.2M | 11% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
